At the forefront of cystic fibrosis research, Sionna Therapeutics recently unveiled critical preclinical findings on their innovative Series 2 NBD1 stabilizers at the 2023 North American Cystic Fibrosis Conference. The company’s stabilizers, SION-719 and SION-451, have demonstrated the potential to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in preclinical […]
Sage Therapeutics has secured a global collaboration and licensing deal worth up to $3.1 billion with Biogen for two of its drug candidates intended for the treatment of depression and movement disorders. Under the terms of the deal, the two US pharma companies will jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), […]
CNS biopharma company Sage Therapeutics is all set to commercially launch its ZULRESSO (brexanolone) injection in the US later this month for the treatment of postpartum depression (PPD), a major depressive episode that can occur during pregnancy or after delivery. Sage Therapeutics said that the US Drug Enforcement Administration (DEA) has put ZULRESSO into Schedule […]